These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 2201036)
1. Cancer immunotherapy with autologous and allogeneic vaccines: a practical overview. Shinitzky M; Skornick Y Prog Clin Biol Res; 1990; 348():95-125. PubMed ID: 2201036 [No Abstract] [Full Text] [Related]
2. Fundamentals of active specific immunotherapy of cancer using BCG-tumor cell vaccines. Hanna MG; Peters LC; Hoover HC Prog Clin Biol Res; 1989; 310():51-65. PubMed ID: 2672023 [No Abstract] [Full Text] [Related]
3. Overview of tumor cell-based vaccines. Copier J; Dalgleish A Int Rev Immunol; 2006; 25(5-6):297-319. PubMed ID: 17169778 [TBL] [Abstract][Full Text] [Related]
4. [Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens]. Prikler L; Scandella E; Men Y; Engeler DS; Diener PA; Gillessen S; Ludewig B; Schmid HP Aktuelle Urol; 2004 Aug; 35(4):326-30. PubMed ID: 15459874 [TBL] [Abstract][Full Text] [Related]
5. Virus modified tumor cell vaccines for active specific immunotherapy of micrometastases: expansion and activation of tumor-specific T cells. Schirrmacher V; von Hoegen P; Heicappell R Prog Clin Biol Res; 1989; 288():391-9. PubMed ID: 2785693 [No Abstract] [Full Text] [Related]
9. Radiation therapy and immunotherapy: the value of immunotherapy in the control of local and regional cancer. Cancer; 1976 Apr; 37(4 Suppl):2108-19. PubMed ID: 769945 [No Abstract] [Full Text] [Related]
14. RNA loading of leukemic antigens into cord blood-derived dendritic cells for immunotherapy. Hsu AK; Kerr BM; Jones KL; Lock RB; Hart DN; Rice AM Biol Blood Marrow Transplant; 2006 Aug; 12(8):855-67. PubMed ID: 16864056 [TBL] [Abstract][Full Text] [Related]
15. Cyclins against cancer: a novel family of tumor antigens? Klein-González N; Kondo E; von Bergwelt-Baildon MS Immunotherapy; 2010 Sep; 2(5):595-7. PubMed ID: 20874640 [No Abstract] [Full Text] [Related]
16. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies. Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962 [TBL] [Abstract][Full Text] [Related]
17. The potential of melanoma antigen expression in cancer therapy. Gillespie AM; Coleman RE Cancer Treat Rev; 1999 Aug; 25(4):219-27. PubMed ID: 10448130 [TBL] [Abstract][Full Text] [Related]
18. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase. LaTemple DC; Abrams JT; Zhang SY; Galili U Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604 [TBL] [Abstract][Full Text] [Related]
19. [Identification of cancer antigens of relevance for specific cancer immunotherapy]. van den Eynde B Bull Mem Acad R Med Belg; 2001; 156(10-12):548-55. PubMed ID: 12371273 [TBL] [Abstract][Full Text] [Related]